Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377:1345–56. https://doi.org/10.1056/nejmoa1709684.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schina A, Pedersen S, Spenning AL, et al. Sustained improved survival of patients with metastatic melanoma after the introduction of anti-PD-1-based therapies. Eur J Cancer. 2023. https://doi.org/10.1016/j.ejca.2023.113392.

Article  PubMed  Google Scholar 

Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381:626–36. https://doi.org/10.1056/nejmoa1904059.

Article  CAS  PubMed  Google Scholar 

Ascierto PA, Mandaì M, Ferrucci PF, et al. Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): a randomized, three-arm, open-label phase II trial. J Clin Oncol. 2022;41:212–21. https://doi.org/10.1200/JCO.21.

Article  PubMed  Google Scholar 

Atkins MB, Lee SJ, Chmielowski B, et al. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2022;41:186–97. https://doi.org/10.1200/JCO.22.

Article  PubMed  PubMed Central  Google Scholar 

Wolchok JD, Chiarion-Sileni V, Rutkowski P, et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2024. https://doi.org/10.1056/NEJMoa2407417.

Article  PubMed  PubMed Central  Google Scholar 

van Not OJ, van den Eertwegh AJM, Jalving H, et al. Long-term survival in patients with advanced melanoma. JAMA Netw Open. 2024;7: e2426641. https://doi.org/10.1001/jamanetworkopen.2024.26641.

Article  PubMed  PubMed Central  Google Scholar 

Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022;10: e005755. https://doi.org/10.1136/jitc-2022-005755.

Article  PubMed  PubMed Central  Google Scholar 

Kluger HM, Tawbi HA, Ascierto ML, et al. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. J Immunother Cancer. 2020;8: e000398. https://doi.org/10.1136/jitc-2019-000398.

Article  PubMed  PubMed Central  Google Scholar 

Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168:707–23.

CAS  PubMed  PubMed Central  Google Scholar 

Cristescu R, Aurora-Garg D, Albright A, et al. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors. J Immunother Cancer. 2022;10: e003091. https://doi.org/10.1136/jitc-2021-003091.

Article  PubMed  PubMed Central  Google Scholar 

Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Sci New Series. 2015;348:69–74.

CAS  Google Scholar 

Wang H, Liu B, Wei J. Beta2-microglobulin(B2M) in cancer immunotherapies: biological function, resistance and remedy. Cancer Lett. 2021;517:96–104.

CAS  PubMed  Google Scholar 

Fenton SE, Saleiro D, Platanias LC. Type i and ii interferons in the anti-tumor immune response. Cancers (Basel). 2021;13:1–19.

Google Scholar 

Schiantarelli J, Benamar M, Park J, et al. Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma. Cancer Cell. 2025;43:308-16.e6. https://doi.org/10.1016/j.ccell.2025.01.009.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jaiswal AR, Liu AJ, Pudakalakatti S, et al. Melanoma evolves complete immunotherapy resistance through the acquisition of a hypermetabolic phenotype. Cancer Immunol Res. 2020;8:1365–80. https://doi.org/10.1158/2326-6066.CIR-19-0005.

Article  PubMed  PubMed Central  Google Scholar 

Chang CH, Qiu J, O’Sullivan D, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162:1229–41. https://doi.org/10.1016/j.cell.2015.08.016.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang T, Jia Y, Yu Y, et al. Targeting the tumor biophysical microenvironment to reduce resistance to immunotherapy. Adv Drug Deliv Rev. 2022;186: 114319. https://doi.org/10.1016/j.addr.2022.114319.

Article  CAS  PubMed  Google Scholar 

Andersen MH. Tumor microenvironment antigens. Semin Immunopathol. 2023;45:253–64.

CAS  PubMed  Google Scholar 

Cabrita R, Lauss M, Sanna A, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577:561–5. https://doi.org/10.1038/s41586-019-1914-8.

Article  CAS  PubMed  Google Scholar 

Fan P, Zhang N, Candi E, et al. Alleviating hypoxia to improve cancer immunotherapy. Oncogene. 2023;42:3591–604.

CAS  PubMed  Google Scholar 

Derosa L, Routy B, Desilets A, et al. Microbiota-centered interventions: the next breakthrough in immuno-oncology? Cancer Discov. 2021;11:2396–412. https://doi.org/10.1158/2159-8290.CD-21-0236.

Article  CAS  PubMed  Google Scholar 

Routy B, Gopalakrishnan V, Daillère R, et al. The gut microbiota influences anticancer immunosurveillance and general health. Nat Rev Clin Oncol. 2018;15:382–96.

CAS  PubMed  Google Scholar 

Lee KA, Thomas AM, Bolte LA, et al. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nat Med. 2022;28:535–44. https://doi.org/10.1038/s41591-022-01695-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aghamajidi A, Maleki VS. The effect of the gut microbiota on systemic and anti-tumor immunity and response to systemic therapy against cancer. Cancers (Basel). 2022;14:3563. https://doi.org/10.3390/cancers14153563.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Verdys P, Johansen A, Anurag G, et al. Acquired resistance to immunotherapy in solid tumor. Trends Mol Med. 2025. https://doi.org/10.1016/j.molmed.2025.03.010.

Article  PubMed  Google Scholar 

Sorroche BP, Teixeira RJ, Pereira CAD, et al. PD-L1 tumor expression as a predictive biomarker of immune checkpoint inhibitors’ response and survival in advanced melanoma patients in Brazil. Diagnostics. 2023;13:1041. https://doi.org/10.3390/diagnostics13061041.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vestergaard C, Donia M, Madsen K, et al. Impact of assessment-to-treatment interval and metastatic biopsy site on the predictive value of PD-L1 expression at the 1% cut-off level in melanoma. Eur J Cancer. 2025;221: 115402.

CAS  PubMed  Google Scholar 

Schmitt AM, Larkin J, Patel SP. Dual immune checkpoint inhibition in melanoma and PD-L1 expression: the jury is still out. J Clin Oncol. 2024;43:122–4. https://doi.org/10.1200/JCO-24-01572.

Article  CAS  PubMed  Google Scholar 

Donia M, Prasad V. Dual checkpoint inhibition in melanoma with ≥ 1% PD-L1: time to reassess the evidence. JAMA Oncol. 2024;10:860–2.

PubMed  Google Scholar 

Donia M, Svane IM. PD-L1 expression for tailoring treatment in advanced melanoma: it is never that easy: reply. JAMA Oncol. 2024;10:1733–4.

Google Scholar